Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695529 | 0.83 | — | — | |
| SCHEMBL15406243 | 0.78 | — | — | |
| SCHEMBL170638 | 0.75 | — | — | |
| SCHEMBL7272701 | 0.75 | — | — | |
| Methane SCHEMBL27943234 | 0.73 | — | — | |
| SCHEMBL2489865 | 0.73 | — | — | |
| Ammonia Solution, Strong SCHEMBL88330 | 0.73 | — | — | |
| Charcoal, Activated SCHEMBL4900853 | 0.73 | — | — | |
| SCHEMBL10703460 | 0.72 | — | — | |
| SCHEMBL27281565 | 0.72 | ALDH1A1 (0.53) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | claimed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-4992451-A | Hypotensive agents, calcium blocking agents | SANKYO COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0207674-A2 | 1,4-Dihydropyridine derivatives, their preparation and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | ALDH1A1 580/4885TSHR 900/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | ALDH1A1 580/4885TSHR 900/4885 |
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | NOS1, NOS2, PTGS1 | ALDH1A1 307/4885TSHR 3596/4885 |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | ALDH1A1 883/4885TSHR 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.